Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma

Investigational New Drugs - Tập 9 - Trang 73-75 - 1991
Ralph B. Vance1,2, John J. Crowley1,2, John S. Macdonald1,2, Frederick R. Ahmann1,2
1University of Mississippi Medical Center, Southwest Oncology Group Statistical Center, Seattle
2University of Kentucky Medical Center, University of Arizona Cancer Center, USA

Tóm tắt

Forty-five patients with non-small cell lung cancer were treated in a phase II trial with menogaril 200 mg/m2 IV every twenty-eight days by a one-hour infusion. One partial response was noted while twenty-two patients had stable disease (51 %). Progressive disease was noted in the remaining twenty-two patients. There was one fatal complication due to pancytopenia and pneumonia. Otherwise, the drug was reasonably well tolerated. At this dosage and schedule, menogaril has no substantial anti-tumor activity for patients with non-small cell lung cancer.

Tài liệu tham khảo

Krueger WC, Pschigoda M, Schpok SLF: The interaction of nogalamycin and analogs with DNA and other biopolymers. Chem-Biol Interaction 36: 1–18, 1981 Li LH, Murch LL, Wooden JM, Krueger WC, Pschigoda LM: Inhibition of DNA and RNA polymerases by nogalamycin and its analogs. (Abstr) Proc Am Assoc Cancer Res 19: 30, 1978 Neil GL, Kuentzel SL, McGovren JP: Treatment of mouse tumors with 7-con-O-Methylnogarol and other analogs of the anthracycline antibiotics, nogalamycin. Cancer Treat Rep 63: 1971–1978, 1979 Weiss GR, Bhuyan DK, Kisner DL, Von Hoff DD: 7(R)-O- Methylnogarol (MEN): antitumor activity in the human tumor cloning system. Invest New Drugs 2: 118, 1984 Joss RA et al.: Euro J Cancer Oncol 24 (2): 263–265, 1988